Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation SequencingInvivoscribe Marketing2021-02-11T21:47:46-08:00May 19th, 2020|2020 Publications, Publications| Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United StatesInvivoscribe Marketing2021-02-26T19:09:52-08:00May 19th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe to Participate in Virtual ASCO 2020Invivoscribe Marketing2020-05-27T18:13:43-07:00May 15th, 2020|Events, Upcoming Events| Read more
Invivoscribe to Exhibit at 25th EHA Annual CongressInvivoscribe Marketing2020-05-27T18:11:58-07:00May 15th, 2020|Events, Upcoming Events| Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentInvivoscribe Marketing2021-02-15T19:48:14-08:00May 6th, 2020|2020 Publications, Publications| Read more
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple MyelomaInvivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications| Read more